Revolution Medicines, Inc. · NASDAQ:RVMD
Goldsmith Mark A sold 86,000 Revolution Medicines, Inc. shares (Form 4)
Traded Aug 21, 2026 · Filed Aug 25, 2026
On Aug 21, 2026, Goldsmith Mark A (Director, See Remarks) sold 86,000 Revolution Medicines, Inc. shares at an average US$209.20 for US$18M under a trading plan, leaving 61,424 shares. Filed Aug 25, 2026 (Form 4).
- Sold
- 86,000 shares
- Price
- US$209.20 average (US$207.23 to US$212.08)
- Value
- US$18M
- Holding after
- 61,424 shares (held indirectly)
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director, See Remarks
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Aug 21, 2026 | Common Stock | Option exercise | 80,000 | US$4.73 | 347,330 | Direct |
| Aug 21, 2026 | Common Stock | Sale | 5,128 | US$207.23 | 342,202 | Direct |
| Aug 21, 2026 | Common Stock | Sale | 24,917 | US$208.37 | 317,285 | Direct |
| Aug 21, 2026 | Common Stock | Sale | 35,938 | US$209.26 | 281,347 | Direct |
| Aug 21, 2026 | Common Stock | Sale | 3,813 | US$210.25 | 277,534 | Direct |
| Aug 21, 2026 | Common Stock | Sale | 6,583 | US$211.33 | 270,951 | Direct |
| Aug 21, 2026 | Common Stock | Sale | 3,621 | US$212.08 | 267,330 | Direct |
| Aug 21, 2026 | Common Stock | Sale | 190 | US$207.25 | 64,234 | Indirect |
| Aug 21, 2026 | Common Stock | Sale | 951 | US$208.36 | 63,283 | Indirect |
| Aug 21, 2026 | Common Stock | Sale | 1,351 | US$209.28 | 61,932 | Indirect |
| Aug 21, 2026 | Common Stock | Sale | 136 | US$210.40 | 61,796 | Indirect |
| Aug 21, 2026 | Common Stock | Sale | 245 | US$211.47 | 61,551 | Indirect |
| Aug 21, 2026 | Common Stock | Sale | 127 | US$212.06 | 61,424 | Indirect |
| Aug 21, 2026 | Common Stock | Sale | 177 | US$207.25 | 64,247 | Indirect |
| Aug 21, 2026 | Common Stock | Sale | 937 | US$208.36 | 63,310 | Indirect |
| Aug 21, 2026 | Common Stock | Sale | 1,405 | US$209.27 | 61,905 | Indirect |
| Aug 21, 2026 | Common Stock | Sale | 126 | US$210.40 | 61,779 | Indirect |
| Aug 21, 2026 | Common Stock | Sale | 229 | US$211.46 | 61,550 | Indirect |
| Aug 21, 2026 | Common Stock | Sale | 126 | US$212.06 | 61,424 | Indirect |
Source
Related
- Revolution Medicines, Inc.
- Goldsmith Mark A
- Revolution Medicines, Inc. shareholders
- Form 4 · Goldsmith Mark A · Sep 18, 2026
- Form 4 · Goldsmith Mark A · Jun 18, 2026
- Form 4 · Goldsmith Mark A · Apr 17, 2026
- Form 4 · Sandler Alan B. · Oct 1, 2026
- Form 4 · Cislini Jeff · Sep 29, 2026
- Form 4 · Mancini Anthony · Sep 28, 2026
- Form 4 · Anderson Elizabeth M · Sep 24, 2026
- Form 4 · Mancini Anthony · Sep 22, 2026